Prothena Corp Public (PRTA) Return on Capital Employed (2013 - 2026)
Prothena Corp Public's (PRTA) quarterly Return on Capital Employed came in at 38.92% in Q1 2026, down 960.0% year-on-year from 4.53% in Q1 2025, and up 45.81% quarter-over-quarter from 71.82% in Q4 2025.
Prothena Corp Public (PRTA) Return on Capital Employed (2013 - 2026) Analysis & Trends
Prothena Corp Public's Return on Capital Employed history runs 14 years deep, the most recent figure standing at 38.92% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 960.0% year-over-year to 38.92% in Q1 2026; TTM through Mar 2026 was 38.92%, a 960.0% decrease from a year earlier, with the FY2025 full-year figure at 54.19%, down 2722.0% from the prior year.
- Return on Capital Employed improved to 38.92% in Q1 2026 per PRTA's latest filing, from 71.82% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11.83% in Q1 2022 and bottomed at 78.71% in Q3 2025.
- The 5-year median for Return on Capital Employed is 29.3% (2024), against an average of 31.71%.
- Across the five-year window, Return on Capital Employed surged 4788 bps in 2022 and tumbled 5868 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 21.71% in 2022, then sank by 32 bps to 28.74% in 2023, then decreased by 3 bps to 29.57% in 2024, then slumped by 143 bps to 71.82% in 2025, then jumped by 46 bps to 38.92% in 2026.
- Per Business Quant, the three latest PRTA Return on Capital Employed figures stand at 38.92% (Q1 2026), 71.82% (Q4 2025), and 78.71% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | -38.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.92% |
| Dec 31, 2025 | -71.82% |
| Sep 30, 2025 | -78.71% |
| Jun 30, 2025 | -74.23% |
| Mar 31, 2025 | -29.32% |
| Dec 31, 2024 | -29.57% |
| Sep 30, 2024 | -29.30% |
| Jun 30, 2024 | -15.55% |
| Mar 31, 2024 | -35.07% |
| Dec 31, 2023 | -28.74% |
| Sep 30, 2023 | -16.55% |
| Jun 30, 2023 | -26.27% |
| Mar 31, 2023 | -21.39% |
| Dec 31, 2022 | -21.71% |
| Sep 30, 2022 | -32.82% |
| Jun 30, 2022 | -0.96% |
| Mar 31, 2022 | 11.83% |
| Dec 31, 2021 | 12.25% |
| Sep 30, 2021 | 14.79% |
| Jun 30, 2021 | -18.39% |